ES2657061T3 - Inhibición de la cinasa 1 asociada a adaptador para el tratamiento del dolor - Google Patents
Inhibición de la cinasa 1 asociada a adaptador para el tratamiento del dolor Download PDFInfo
- Publication number
- ES2657061T3 ES2657061T3 ES13709722.6T ES13709722T ES2657061T3 ES 2657061 T3 ES2657061 T3 ES 2657061T3 ES 13709722 T ES13709722 T ES 13709722T ES 2657061 T3 ES2657061 T3 ES 2657061T3
- Authority
- ES
- Spain
- Prior art keywords
- pyridazin
- optionally substituted
- halo
- imidazo
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 17
- 108091000080 Phosphotransferase Proteins 0.000 title claims abstract description 12
- 102000020233 phosphotransferase Human genes 0.000 title claims abstract description 12
- 208000002193 Pain Diseases 0.000 title description 23
- 230000005764 inhibitory process Effects 0.000 title description 10
- -1 aryl-C1-C3 alkyl Chemical group 0.000 claims abstract description 292
- 150000001875 compounds Chemical class 0.000 claims abstract description 150
- 125000001183 hydrocarbyl group Chemical group 0.000 claims abstract description 99
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 77
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 67
- 239000001257 hydrogen Substances 0.000 claims abstract description 67
- 238000006467 substitution reaction Methods 0.000 claims abstract description 64
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 48
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 39
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 19
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims abstract description 17
- 125000003118 aryl group Chemical group 0.000 claims abstract description 17
- 150000002431 hydrogen Chemical group 0.000 claims abstract description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 15
- 239000003112 inhibitor Substances 0.000 claims abstract description 15
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims abstract description 14
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims abstract description 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 10
- 230000000694 effects Effects 0.000 claims abstract description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 9
- 125000004992 haloalkylamino group Chemical group 0.000 claims abstract description 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims abstract description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 8
- 208000001640 Fibromyalgia Diseases 0.000 claims abstract description 7
- 125000003282 alkyl amino group Chemical group 0.000 claims abstract description 7
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 125000005221 halo alkyl carbonyl amino group Chemical group 0.000 claims abstract description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims abstract description 5
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 claims abstract description 4
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims abstract description 4
- 125000001769 aryl amino group Chemical group 0.000 claims abstract description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 4
- 125000006677 (C1-C3) haloalkoxy group Chemical group 0.000 claims abstract description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract description 3
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims abstract description 3
- 125000004658 aryl carbonyl amino group Chemical group 0.000 claims abstract description 3
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims abstract description 3
- 125000001475 halogen functional group Chemical group 0.000 claims abstract 35
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000005169 cycloalkylcarbonylamino group Chemical group 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 98
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 75
- 125000005843 halogen group Chemical group 0.000 description 59
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 23
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 19
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 125000004076 pyridyl group Chemical group 0.000 description 16
- 238000000034 method Methods 0.000 description 14
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000007792 addition Methods 0.000 description 9
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 239000006180 TBST buffer Substances 0.000 description 7
- 101150118144 aak-1 gene Proteins 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 6
- 229960002870 gabapentin Drugs 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000007726 management method Methods 0.000 description 6
- 125000003386 piperidinyl group Chemical group 0.000 description 6
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 5
- 208000004296 neuralgia Diseases 0.000 description 5
- 208000021722 neuropathic pain Diseases 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- RUZLIIJDZBWWSA-INIZCTEOSA-N methyl 2-[[(1s)-1-(7-methyl-2-morpholin-4-yl-4-oxopyrido[1,2-a]pyrimidin-9-yl)ethyl]amino]benzoate Chemical group COC(=O)C1=CC=CC=C1N[C@@H](C)C1=CC(C)=CN2C(=O)C=C(N3CCOCC3)N=C12 RUZLIIJDZBWWSA-INIZCTEOSA-N 0.000 description 4
- 125000005487 naphthalate group Chemical group 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 235000011007 phosphoric acid Nutrition 0.000 description 4
- 125000004942 pyridazin-6-yl group Chemical group N1=NC=CC=C1* 0.000 description 4
- LCDCPQHFCOBUEF-UHFFFAOYSA-N pyrrolidine-1-carboxamide Chemical compound NC(=O)N1CCCC1 LCDCPQHFCOBUEF-UHFFFAOYSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 201000000980 schizophrenia Diseases 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 229930192474 thiophene Natural products 0.000 description 4
- 230000001256 tonic effect Effects 0.000 description 4
- 229940119498 AAK1 inhibitor Drugs 0.000 description 3
- 102100031315 AP-2 complex subunit mu Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 239000012097 Lipofectamine 2000 Substances 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 150000008378 aryl ethers Chemical class 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- PCDHSSHKDZYLLI-UHFFFAOYSA-N butan-1-one Chemical compound CCC[C]=O PCDHSSHKDZYLLI-UHFFFAOYSA-N 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 125000004404 heteroalkyl group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- DCLWNTIANRACSB-UHFFFAOYSA-N imidazo[1,2-b]pyridazin-6-amine Chemical compound N1=C(N)C=CC2=NC=CN21 DCLWNTIANRACSB-UHFFFAOYSA-N 0.000 description 3
- VTVRXITWWZGKHV-UHFFFAOYSA-N imidazo[1,2-b]pyridazine Chemical compound N1=CC=CC2=NC=CN21 VTVRXITWWZGKHV-UHFFFAOYSA-N 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 230000003040 nociceptive effect Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical compound N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000020341 sensory perception of pain Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- OGGPATCZSITEFC-UHFFFAOYSA-N 2-methylpropanoic acid;piperazine Chemical compound CC(C)C(O)=O.C1CNCCN1 OGGPATCZSITEFC-UHFFFAOYSA-N 0.000 description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- SGAGKHUEALFWOV-UHFFFAOYSA-N 3-[4-(aminomethyl)phenyl]-n-(2-cyclopentyloxyethyl)imidazo[1,2-b]pyridazin-6-amine Chemical compound C1=CC(CN)=CC=C1C1=CN=C2N1N=C(NCCOC1CCCC1)C=C2 SGAGKHUEALFWOV-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- JBOYQZDFEWOILV-UHFFFAOYSA-N 5h-chromene Chemical compound O1C=CC=C2CC=CC=C21 JBOYQZDFEWOILV-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000005672 electromagnetic field Effects 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- QMTYNUZIEQMHMS-UHFFFAOYSA-N n-(2-aminoethyl)-4-[6-(butylamino)imidazo[1,2-b]pyridazin-3-yl]benzamide Chemical compound N12N=C(NCCCC)C=CC2=NC=C1C1=CC=C(C(=O)NCCN)C=C1 QMTYNUZIEQMHMS-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical compound NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 2
- 229960001233 pregabalin Drugs 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical compound CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- PZKCEOJKPXSUHT-IBGZPJMESA-N (2S)-2-amino-N-[[4-[6-(butylamino)imidazo[1,2-b]pyridazin-3-yl]phenyl]methyl]-4-methylpentanamide Chemical compound N[C@H](C(=O)NCC1=CC=C(C=C1)C1=CN=C2N1N=C(C=C2)NCCCC)CC(C)C PZKCEOJKPXSUHT-IBGZPJMESA-N 0.000 description 1
- TUIWYEGMCYHHHP-UHFFFAOYSA-N (4-aminopiperidin-1-yl)-[4-[6-(butylamino)imidazo[1,2-b]pyridazin-3-yl]phenyl]methanone Chemical compound N12N=C(NCCCC)C=CC2=NC=C1C(C=C1)=CC=C1C(=O)N1CCC(N)CC1 TUIWYEGMCYHHHP-UHFFFAOYSA-N 0.000 description 1
- LIFFBYOGDSKMLD-SFHVURJKSA-N (5S)-1-(3,3-dimethylbutyl)-5-[[[3-(2-ethoxyphenyl)pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]pyrrolidin-2-one Chemical compound CC(CCN1C(CC[C@H]1CNC1=NC=2N(C=C1)N=CC=2C1=C(C=CC=C1)OCC)=O)(C)C LIFFBYOGDSKMLD-SFHVURJKSA-N 0.000 description 1
- WXVBEEVAZFDNCW-LBPRGKRZSA-N (5S)-5-[[(3-bromopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]-1-(3,3-dimethylbutyl)pyrrolidin-2-one Chemical compound BrC=1C=NN2C=1N=C(C=C2)NC[C@@H]1CCC(N1CCC(C)(C)C)=O WXVBEEVAZFDNCW-LBPRGKRZSA-N 0.000 description 1
- RGHXJCSKHXCIKU-SFHVURJKSA-N (5s)-1-(3,3-dimethylbutyl)-5-[[(3-phenylpyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]pyrrolidin-2-one Chemical compound C1CC(=O)N(CCC(C)(C)C)[C@@H]1CNC1=NC2=C(C=3C=CC=CC=3)C=NN2C=C1 RGHXJCSKHXCIKU-SFHVURJKSA-N 0.000 description 1
- YPVLYNJWZHZJFK-KRWDZBQOSA-N (5s)-1-(3,3-dimethylbutyl)-5-[[[3-(2-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]pyrrolidin-2-one Chemical compound COC1=CC=CC=C1C1=C2N=C(NC[C@H]3N(C(=O)CC3)CCC(C)(C)C)C=CN2N=C1 YPVLYNJWZHZJFK-KRWDZBQOSA-N 0.000 description 1
- YDWQZVHCHQMSAR-INIZCTEOSA-N (5s)-1-(3,3-dimethylbutyl)-5-[[[3-(2-methoxypyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]pyrrolidin-2-one Chemical compound COC1=NC=CC=C1C1=C2N=C(NC[C@H]3N(C(=O)CC3)CCC(C)(C)C)C=CN2N=C1 YDWQZVHCHQMSAR-INIZCTEOSA-N 0.000 description 1
- IOLXWOHKKBERNG-INIZCTEOSA-N (5s)-1-(3,3-dimethylbutyl)-5-[[[3-(3-methoxypyridin-4-yl)pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]pyrrolidin-2-one Chemical compound COC1=CN=CC=C1C1=C2N=C(NC[C@H]3N(C(=O)CC3)CCC(C)(C)C)C=CN2N=C1 IOLXWOHKKBERNG-INIZCTEOSA-N 0.000 description 1
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 1
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- FLUMVZXZHIKHSM-INIZCTEOSA-N 1-[(2S)-2-[[[3-(2,4-dimethyl-1,3-thiazol-5-yl)imidazo[1,2-b]pyridazin-6-yl]amino]methyl]pyrrolidin-1-yl]-3-methylbutan-1-one Chemical compound CC=1SC(=C(N=1)C)C1=CN=C2N1N=C(C=C2)NC[C@H]1N(CCC1)C(CC(C)C)=O FLUMVZXZHIKHSM-INIZCTEOSA-N 0.000 description 1
- SUAJUFUSAORJLF-INIZCTEOSA-N 1-[(2S)-2-[[[3-(2-fluoropyridin-4-yl)imidazo[1,2-b]pyridazin-6-yl]amino]methyl]pyrrolidin-1-yl]-3-methylbutan-1-one Chemical compound FC1=NC=CC(=C1)C1=CN=C2N1N=C(C=C2)NC[C@H]1N(CCC1)C(CC(C)C)=O SUAJUFUSAORJLF-INIZCTEOSA-N 0.000 description 1
- GEIJQDFXPDWEDZ-INIZCTEOSA-N 1-[(2S)-2-[[[3-(2-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-5-yl]amino]methyl]pyrrolidin-1-yl]butan-1-one Chemical compound COC1=C(C=CC=C1)C=1C=NN2C=1N=C(C=C2)NC[C@H]1N(CCC1)C(CCC)=O GEIJQDFXPDWEDZ-INIZCTEOSA-N 0.000 description 1
- ZOEZWGGMWFGQSP-UHFFFAOYSA-N 1-[2-[[3-[4-(aminomethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]amino]ethyl]-3-tert-butylimidazolidin-2-one Chemical compound O=C1N(C(C)(C)C)CCN1CCNC1=NN2C(C=3C=CC(CN)=CC=3)=CN=C2C=C1 ZOEZWGGMWFGQSP-UHFFFAOYSA-N 0.000 description 1
- NSDSPGFUHDIDJE-UHFFFAOYSA-N 1-[3-[3-[4-(aminomethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]phenyl]ethanone Chemical compound CC(=O)C1=CC=CC(C2=NN3C(C=4C=CC(CN)=CC=4)=CN=C3C=C2)=C1 NSDSPGFUHDIDJE-UHFFFAOYSA-N 0.000 description 1
- LYDGRNUEVMWEDD-UHFFFAOYSA-N 1-[4-[3-(2-methoxypyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl]piperazin-1-yl]-3-methylbutan-1-one Chemical compound COC1=NC=CC=C1C=1C=NN2C=1N=C(C=C2)N1CCN(CC1)C(CC(C)C)=O LYDGRNUEVMWEDD-UHFFFAOYSA-N 0.000 description 1
- UIRIMMUUGLAJJD-UHFFFAOYSA-N 1-[5-[6-(2-methylpropylamino)imidazo[1,2-b]pyridazin-3-yl]thiophen-2-yl]ethanone Chemical compound C(C(C)C)NC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(S1)C(C)=O UIRIMMUUGLAJJD-UHFFFAOYSA-N 0.000 description 1
- XPDCJDXRIXZRBI-UHFFFAOYSA-N 1-[5-[6-(3-methoxypropylamino)imidazo[1,2-b]pyridazin-3-yl]thiophen-2-yl]ethanone Chemical compound COCCCNC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(S1)C(C)=O XPDCJDXRIXZRBI-UHFFFAOYSA-N 0.000 description 1
- VOSPMSKSBAJETI-UHFFFAOYSA-N 1-[5-[6-(propylamino)imidazo[1,2-b]pyridazin-3-yl]thiophen-2-yl]ethanone Chemical compound N12N=C(NCCC)C=CC2=NC=C1C1=CC=C(C(C)=O)S1 VOSPMSKSBAJETI-UHFFFAOYSA-N 0.000 description 1
- JDCJHEXTOKVJDK-UHFFFAOYSA-N 1-[5-[6-[3-(methylamino)propylamino]imidazo[1,2-b]pyridazin-3-yl]thiophen-2-yl]ethanone Chemical compound N12N=C(NCCCNC)C=CC2=NC=C1C1=CC=C(C(C)=O)S1 JDCJHEXTOKVJDK-UHFFFAOYSA-N 0.000 description 1
- AKQNOSJDZBJVJY-UHFFFAOYSA-N 1-[5-[6-[butyl(methyl)amino]imidazo[1,2-b]pyridazin-3-yl]thiophen-2-yl]ethanone Chemical compound N12N=C(N(C)CCCC)C=CC2=NC=C1C1=CC=C(C(C)=O)S1 AKQNOSJDZBJVJY-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- XWZNSKGBRYPJRQ-UHFFFAOYSA-N 1-tert-butyl-3-[2-[[3-(3-methoxypyridin-4-yl)imidazo[1,2-b]pyridazin-6-yl]amino]ethyl]imidazolidin-2-one Chemical compound C(C)(C)(C)N1C(N(CC1)CCNC=1C=CC=2N(N=1)C(=CN=2)C1=C(C=NC=C1)OC)=O XWZNSKGBRYPJRQ-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- VADAUYZMBOTUPF-UHFFFAOYSA-N 2,2-dimethyl-1-[4-(3-phenylimidazo[1,2-b]pyridazin-6-yl)piperazin-1-yl]propan-1-one Chemical compound C1CN(C(=O)C(C)(C)C)CCN1C1=NN2C(C=3C=CC=CC=3)=CN=C2C=C1 VADAUYZMBOTUPF-UHFFFAOYSA-N 0.000 description 1
- 125000006069 2,3-dimethyl-2-butenyl group Chemical group 0.000 description 1
- LXFQSRIDYRFTJW-UHFFFAOYSA-M 2,4,6-trimethylbenzenesulfonate Chemical compound CC1=CC(C)=C(S([O-])(=O)=O)C(C)=C1 LXFQSRIDYRFTJW-UHFFFAOYSA-M 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical group O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- ZOLKPPWPMIMABK-UHFFFAOYSA-N 2-fluoroethyl 4-[3-(2-methoxypyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl]piperazine-1-carboxylate Chemical compound COC1=NC=CC=C1C=1C=NN2C=1N=C(C=C2)N1CCN(CC1)C(=O)OCCF ZOLKPPWPMIMABK-UHFFFAOYSA-N 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- SZIALDGHMAOXCW-UHFFFAOYSA-N 2-methoxyethyl 4-[3-(2-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-5-yl]piperazine-1-carboxylate Chemical compound COC1=C(C=CC=C1)C=1C=NN2C=1N=C(C=C2)N1CCN(CC1)C(=O)OCCOC SZIALDGHMAOXCW-UHFFFAOYSA-N 0.000 description 1
- IYNBELLOHXMHJN-UHFFFAOYSA-N 2-methoxyethyl 4-[3-(2-methoxypyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCCOC)CCN1C1=NC2=C(C=3C(=NC=CC=3)OC)C=NN2C=C1 IYNBELLOHXMHJN-UHFFFAOYSA-N 0.000 description 1
- 125000006029 2-methyl-2-butenyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- KQHMXSOKEOOXII-UHFFFAOYSA-N 3-(2-methoxyphenyl)-N-[2-(2-methylpropoxy)ethyl]imidazo[1,2-b]pyridazin-6-amine Chemical compound C(C(C)C)OCCNC=1C=CC=2N(N=1)C(=CN=2)C1=C(C=CC=C1)OC KQHMXSOKEOOXII-UHFFFAOYSA-N 0.000 description 1
- BIGNETGYIAEGCW-UHFFFAOYSA-N 3-(2-methoxypyridin-3-yl)-5-[4-(2-methylpropylsulfonyl)piperazin-1-yl]pyrazolo[1,5-a]pyrimidine Chemical compound C(C(C)C)S(=O)(=O)N1CCN(CC1)C1=NC=2N(C=C1)N=CC=2C=1C(=NC=CC=1)OC BIGNETGYIAEGCW-UHFFFAOYSA-N 0.000 description 1
- XWHNIRDWAJYSBH-UHFFFAOYSA-N 3-(2-methoxypyridin-3-yl)-N-(4,4,4-trifluorobutyl)pyrazolo[1,5-a]pyrimidin-5-amine Chemical compound COC1=NC=CC=C1C=1C=NN2C=1N=C(C=C2)NCCCC(F)(F)F XWHNIRDWAJYSBH-UHFFFAOYSA-N 0.000 description 1
- OOXITNVPDLOHLB-UHFFFAOYSA-N 3-(3-methoxypyridin-4-yl)-N-(3-methylbutyl)imidazo[1,2-b]pyridazin-6-amine Chemical compound C(CC(C)C)NC=1C=CC=2N(N=1)C(=CN=2)C1=C(C=NC=C1)OC OOXITNVPDLOHLB-UHFFFAOYSA-N 0.000 description 1
- QAONRPGUFJDMNK-UHFFFAOYSA-N 3-(3-methoxypyridin-4-yl)-N-[2-(2-methylpropoxy)ethyl]imidazo[1,2-b]pyridazin-6-amine Chemical compound C(C(C)C)OCCNC=1C=CC=2N(N=1)C(=CN=2)C1=C(C=NC=C1)OC QAONRPGUFJDMNK-UHFFFAOYSA-N 0.000 description 1
- ZNUOMPJZHHBEMZ-UHFFFAOYSA-N 3-(3-methoxypyridin-4-yl)-N-[2-[(2-methylpropan-2-yl)oxy]ethyl]imidazo[1,2-b]pyridazin-6-amine Chemical compound C(C)(C)(C)OCCNC=1C=CC=2N(N=1)C(=CN=2)C1=C(C=NC=C1)OC ZNUOMPJZHHBEMZ-UHFFFAOYSA-N 0.000 description 1
- JGTQXOJIWPTYPZ-UHFFFAOYSA-N 3-(3-methoxypyridin-4-yl)-N-[2-[(2-methylpropan-2-yl)oxy]ethyl]pyrazolo[1,5-a]pyrimidin-5-amine Chemical compound C(C)(C)(C)OCCNC1=NC=2N(C=C1)N=CC=2C1=C(C=NC=C1)OC JGTQXOJIWPTYPZ-UHFFFAOYSA-N 0.000 description 1
- XJULPMQNHGYPNA-UHFFFAOYSA-N 3-(3-methoxypyridin-4-yl)-N-[3-[(2-methylpropan-2-yl)oxy]propyl]imidazo[1,2-b]pyridazin-6-amine Chemical compound C(C)(C)(C)OCCCNC=1C=CC=2N(N=1)C(=CN=2)C1=C(C=NC=C1)OC XJULPMQNHGYPNA-UHFFFAOYSA-N 0.000 description 1
- GZTCXHSJROZQHC-UHFFFAOYSA-N 3-(3-methoxypyridin-4-yl)-n-(2-propan-2-yloxyethyl)imidazo[1,2-b]pyridazin-6-amine Chemical compound COC1=CN=CC=C1C1=CN=C2N1N=C(NCCOC(C)C)C=C2 GZTCXHSJROZQHC-UHFFFAOYSA-N 0.000 description 1
- YCOVBLCCASRTKP-UHFFFAOYSA-N 3-(3-methoxypyridin-4-yl)-n-[2-[2-(trifluoromethoxy)phenyl]ethyl]pyrazolo[1,5-a]pyrimidin-5-amine Chemical compound COC1=CN=CC=C1C1=C2N=C(NCCC=3C(=CC=CC=3)OC(F)(F)F)C=CN2N=C1 YCOVBLCCASRTKP-UHFFFAOYSA-N 0.000 description 1
- QYRZGZAYAFNBSR-UHFFFAOYSA-N 3-(4-methoxypyridin-3-yl)-N-[2-[2-(trifluoromethoxy)phenyl]ethyl]pyrazolo[1,5-a]pyrimidin-5-amine Chemical compound COC1=C(C=NC=C1)C=1C=NN2C=1N=C(C=C2)NCCC1=C(C=CC=C1)OC(F)(F)F QYRZGZAYAFNBSR-UHFFFAOYSA-N 0.000 description 1
- YZLMKQZXLZQDGH-UHFFFAOYSA-N 3-[2-(difluoromethoxy)phenyl]-6-piperazin-1-ylimidazo[1,2-b]pyridazine 2-methylpropanoic acid Chemical compound C(C)(C)C(=O)O.FC(OC1=C(C=CC=C1)C1=CN=C2N1N=C(C=C2)N2CCNCC2)F YZLMKQZXLZQDGH-UHFFFAOYSA-N 0.000 description 1
- UHCHMVDVZRHYRG-UHFFFAOYSA-N 3-[4-(aminomethyl)phenyl]-N-(2-cyclopentyloxyethyl)pyrazolo[1,5-a]pyrimidin-5-amine Chemical compound NCC1=CC=C(C=C1)C=1C=NN2C=1N=C(C=C2)NCCOC1CCCC1 UHCHMVDVZRHYRG-UHFFFAOYSA-N 0.000 description 1
- GUPPORCCVIISGY-UHFFFAOYSA-N 3-[4-(aminomethyl)phenyl]-N-(2-methoxyethyl)pyrazolo[1,5-a]pyrimidin-5-amine Chemical compound NCC1=CC=C(C=C1)C=1C=NN2C=1N=C(C=C2)NCCOC GUPPORCCVIISGY-UHFFFAOYSA-N 0.000 description 1
- QGRBUHSFNAZRAC-UHFFFAOYSA-N 3-[4-(aminomethyl)phenyl]-N-(3-cyclopentyloxypropyl)pyrazolo[1,5-a]pyrimidin-5-amine Chemical compound NCC1=CC=C(C=C1)C=1C=NN2C=1N=C(C=C2)NCCCOC1CCCC1 QGRBUHSFNAZRAC-UHFFFAOYSA-N 0.000 description 1
- JKOXEYUSPOMHQP-UHFFFAOYSA-N 3-[4-(aminomethyl)phenyl]-N-[2-(2,2-dimethylpropoxy)ethyl]pyrazolo[1,5-a]pyrimidin-5-amine Chemical compound NCC1=CC=C(C=C1)C=1C=NN2C=1N=C(C=C2)NCCOCC(C)(C)C JKOXEYUSPOMHQP-UHFFFAOYSA-N 0.000 description 1
- LJRXAQQBESZCRT-UHFFFAOYSA-N 3-[4-(aminomethyl)phenyl]-N-[2-[(2-methylpropan-2-yl)oxy]ethyl]pyrazolo[1,5-a]pyrimidin-5-amine Chemical compound NCC1=CC=C(C=C1)C=1C=NN2C=1N=C(C=C2)NCCOC(C)(C)C LJRXAQQBESZCRT-UHFFFAOYSA-N 0.000 description 1
- BWUSUDNOPJJXMU-UHFFFAOYSA-N 3-[4-(aminomethyl)phenyl]-N-[2-[2-(trifluoromethoxy)phenyl]ethyl]pyrazolo[1,5-a]pyrimidin-5-amine Chemical compound NCC1=CC=C(C=C1)C=1C=NN2C=1N=C(C=C2)NCCC1=C(C=CC=C1)OC(F)(F)F BWUSUDNOPJJXMU-UHFFFAOYSA-N 0.000 description 1
- XDPOTONVFNIXEC-HNNXBMFYSA-N 3-[4-(aminomethyl)phenyl]-N-[[(2S)-oxolan-2-yl]methyl]imidazo[1,2-b]pyridazin-6-amine Chemical compound NCC1=CC=C(C=C1)C1=CN=C2N1N=C(C=C2)NC[C@H]1OCCC1 XDPOTONVFNIXEC-HNNXBMFYSA-N 0.000 description 1
- MZWMHMQTFYHSNA-UHFFFAOYSA-N 3-[4-(aminomethyl)phenyl]-n-(3-phenylpropyl)imidazo[1,2-b]pyridazin-6-amine Chemical compound C1=CC(CN)=CC=C1C1=CN=C2N1N=C(NCCCC=1C=CC=CC=1)C=C2 MZWMHMQTFYHSNA-UHFFFAOYSA-N 0.000 description 1
- OFXOGGHSLXQKSA-UHFFFAOYSA-N 3-[4-(aminomethyl)phenyl]-n-[2-[(2-methylpropan-2-yl)oxy]ethyl]imidazo[1,2-b]pyridazin-6-amine Chemical compound N12N=C(NCCOC(C)(C)C)C=CC2=NC=C1C1=CC=C(CN)C=C1 OFXOGGHSLXQKSA-UHFFFAOYSA-N 0.000 description 1
- HUJMHXZAAUGMLK-UHFFFAOYSA-N 3-[4-(aminomethyl)phenyl]-n-[3-[(2-methylpropan-2-yl)oxy]propyl]imidazo[1,2-b]pyridazin-6-amine Chemical compound N12N=C(NCCCOC(C)(C)C)C=CC2=NC=C1C1=CC=C(CN)C=C1 HUJMHXZAAUGMLK-UHFFFAOYSA-N 0.000 description 1
- QIFIVTBLADGCPB-UHFFFAOYSA-N 3-[4-(aminomethyl)phenyl]-n-butylpyrazolo[1,5-a]pyrimidin-5-amine Chemical compound C=12N=C(NCCCC)C=CN2N=CC=1C1=CC=C(CN)C=C1 QIFIVTBLADGCPB-UHFFFAOYSA-N 0.000 description 1
- GCXWFHVBQISTDD-UHFFFAOYSA-N 3-bromo-N-(3-cyclopentyloxypropyl)pyrazolo[1,5-a]pyrimidin-5-amine Chemical compound BrC=1C=NN2C=1N=C(C=C2)NCCCOC1CCCC1 GCXWFHVBQISTDD-UHFFFAOYSA-N 0.000 description 1
- GDVCIJCQGRADMG-UHFFFAOYSA-N 3-bromo-N-[[1-(2,2,2-trifluoroethyl)pyrrolidin-2-yl]methyl]pyrazolo[1,5-a]pyrimidin-5-amine Chemical compound BrC=1C=NN2C=1N=C(C=C2)NCC1N(CCC1)CC(F)(F)F GDVCIJCQGRADMG-UHFFFAOYSA-N 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- POVSVAVYFSMPFA-SFHVURJKSA-N 3-methyl-1-[(2S)-2-[[(3-phenylimidazo[1,2-b]pyridazin-6-yl)amino]methyl]pyrrolidin-1-yl]butan-1-one Chemical compound CC(CC(=O)N1[C@@H](CCC1)CNC=1C=CC=2N(N=1)C(=CN=2)C1=CC=CC=C1)C POVSVAVYFSMPFA-SFHVURJKSA-N 0.000 description 1
- 125000006027 3-methyl-1-butenyl group Chemical group 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- BOBCPNNCJIKKMI-UHFFFAOYSA-N 4-[5-(butylamino)pyrazolo[1,5-a]pyrimidin-3-yl]-N-[2-(methylamino)ethyl]benzamide Chemical compound C(CCC)NC1=NC=2N(C=C1)N=CC=2C1=CC=C(C(=O)NCCNC)C=C1 BOBCPNNCJIKKMI-UHFFFAOYSA-N 0.000 description 1
- PBWFEUKNBKFAJR-UHFFFAOYSA-N 4-[6-(butylamino)imidazo[1,2-b]pyridazin-3-yl]-2-fluoro-N-[2-(methylamino)ethyl]benzamide Chemical compound C(CCC)NC=1C=CC=2N(N=1)C(=CN=2)C1=CC(=C(C(=O)NCCNC)C=C1)F PBWFEUKNBKFAJR-UHFFFAOYSA-N 0.000 description 1
- SWFDJQFIYBRZOX-UHFFFAOYSA-N 4-[6-(butylamino)imidazo[1,2-b]pyridazin-3-yl]-N-[2-(diethylamino)ethyl]benzamide Chemical compound C(CCC)NC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(C(=O)NCCN(CC)CC)C=C1 SWFDJQFIYBRZOX-UHFFFAOYSA-N 0.000 description 1
- CYNJYHGPPAAKMT-UHFFFAOYSA-N 4-[6-(butylamino)imidazo[1,2-b]pyridazin-3-yl]-N-[2-(dimethylamino)ethyl]benzamide Chemical compound C(CCC)NC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(C(=O)NCCN(C)C)C=C1 CYNJYHGPPAAKMT-UHFFFAOYSA-N 0.000 description 1
- VIGJJSNGLQFIIS-UHFFFAOYSA-N 4-[6-(butylamino)imidazo[1,2-b]pyridazin-3-yl]-N-[2-(methylamino)ethyl]benzamide Chemical compound C(CCC)NC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(C(=O)NCCNC)C=C1 VIGJJSNGLQFIIS-UHFFFAOYSA-N 0.000 description 1
- MPRHJPSQNMKDAH-UHFFFAOYSA-N 4-[6-(butylamino)imidazo[1,2-b]pyridazin-3-yl]benzamide Chemical compound N12N=C(NCCCC)C=CC2=NC=C1C1=CC=C(C(N)=O)C=C1 MPRHJPSQNMKDAH-UHFFFAOYSA-N 0.000 description 1
- DUGWUNUOLYYDCC-UHFFFAOYSA-N 4-[6-[2-(2-ethoxyphenyl)ethylamino]imidazo[1,2-b]pyridazin-3-yl]-N-methylbenzamide Chemical compound C(C)OC1=C(C=CC=C1)CCNC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(C(=O)NC)C=C1 DUGWUNUOLYYDCC-UHFFFAOYSA-N 0.000 description 1
- PFRSMWLVYKQESM-UHFFFAOYSA-N 5-[6-(butylamino)imidazo[1,2-b]pyridazin-3-yl]thiophene-2-carboxamide Chemical compound C(CCC)NC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(S1)C(=O)N PFRSMWLVYKQESM-UHFFFAOYSA-N 0.000 description 1
- WGNBBRVKHAKQER-UHFFFAOYSA-N 5-[6-(propylamino)imidazo[1,2-b]pyridazin-3-yl]thiophene-2-carbaldehyde Chemical compound C(CC)NC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(S1)C=O WGNBBRVKHAKQER-UHFFFAOYSA-N 0.000 description 1
- BVUNDOBADMJWHI-UHFFFAOYSA-N 6-(butylamino)-N-(1H-pyrazol-4-yl)imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound C(CCC)NC=1C=CC=2N(N=1)C(=CN=2)C(=O)NC=1C=NNC=1 BVUNDOBADMJWHI-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 101150095401 AURKA gene Proteins 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- QNGZHLKMHUXTDE-UHFFFAOYSA-N C(C)(C)C(=O)O.C(C)(C)C=1C=NN2C1N=C(C=C2)N2CCNCC2 Chemical compound C(C)(C)C(=O)O.C(C)(C)C=1C=NN2C1N=C(C=C2)N2CCNCC2 QNGZHLKMHUXTDE-UHFFFAOYSA-N 0.000 description 1
- MQYUTZBERIMPMN-UHFFFAOYSA-N C(C)(C)C(=O)O.C(C)NC(=O)C=1C=NN2C1N=C(C=C2)N2CCNCC2 Chemical compound C(C)(C)C(=O)O.C(C)NC(=O)C=1C=NN2C1N=C(C=C2)N2CCNCC2 MQYUTZBERIMPMN-UHFFFAOYSA-N 0.000 description 1
- LUDDPCYMSFAKBU-UHFFFAOYSA-N C(C)(C)C(=O)O.CC1=NC=CC=C1C=1C=NN2C1N=C(C=C2)N2CCNCC2 Chemical compound C(C)(C)C(=O)O.CC1=NC=CC=C1C=1C=NN2C1N=C(C=C2)N2CCNCC2 LUDDPCYMSFAKBU-UHFFFAOYSA-N 0.000 description 1
- ZZXVXOHWGFNEBB-UHFFFAOYSA-N C(C)(C)C(=O)O.CNC(=O)C=1C=NN2C1N=C(C=C2)N2CCNCC2 Chemical compound C(C)(C)C(=O)O.CNC(=O)C=1C=NN2C1N=C(C=C2)N2CCNCC2 ZZXVXOHWGFNEBB-UHFFFAOYSA-N 0.000 description 1
- IEAUREHGOWJCDG-UHFFFAOYSA-N C(C)(C)C(=O)O.COC1=NC(=CC=C1C=1C=NN2C1N=C(C=C2)N2CCNCC2)C Chemical compound C(C)(C)C(=O)O.COC1=NC(=CC=C1C=1C=NN2C1N=C(C=C2)N2CCNCC2)C IEAUREHGOWJCDG-UHFFFAOYSA-N 0.000 description 1
- FKELMTYVFZYQQS-UHFFFAOYSA-N C(C)(C)C(=O)O.COC1=NC=C(C=C1C=1C=NN2C1N=C(C=C2)N2CCNCC2)C Chemical compound C(C)(C)C(=O)O.COC1=NC=C(C=C1C=1C=NN2C1N=C(C=C2)N2CCNCC2)C FKELMTYVFZYQQS-UHFFFAOYSA-N 0.000 description 1
- GVDRUIMPSKJYBW-UHFFFAOYSA-N C(C)(C)C(=O)O.COC1=NC=CC(=C1)C1=CN=C2N1N=C(C=C2)N2CCNCC2 Chemical compound C(C)(C)C(=O)O.COC1=NC=CC(=C1)C1=CN=C2N1N=C(C=C2)N2CCNCC2 GVDRUIMPSKJYBW-UHFFFAOYSA-N 0.000 description 1
- ABVJQFRWBCJQJP-UHFFFAOYSA-N C(C)(C)C(=O)O.COC1=NC=CC=C1C1=CN=C2N1N=C(C=C2)N2CCNCC2 Chemical compound C(C)(C)C(=O)O.COC1=NC=CC=C1C1=CN=C2N1N=C(C=C2)N2CCNCC2 ABVJQFRWBCJQJP-UHFFFAOYSA-N 0.000 description 1
- MNMMZDFYCIFWAT-UHFFFAOYSA-N C(C)(C)C(=O)O.COC=1C=NC=CC1C1=CN=C2N1N=C(C=C2)N2CCNCC2 Chemical compound C(C)(C)C(=O)O.COC=1C=NC=CC1C1=CN=C2N1N=C(C=C2)N2CCNCC2 MNMMZDFYCIFWAT-UHFFFAOYSA-N 0.000 description 1
- CYQVDXREFBGQCE-UHFFFAOYSA-N C(C)(C)C(=O)O.COC=1N=NC(=CC1C=1C=NN2C1N=C(C=C2)N2CCNCC2)OC Chemical compound C(C)(C)C(=O)O.COC=1N=NC(=CC1C=1C=NN2C1N=C(C=C2)N2CCNCC2)OC CYQVDXREFBGQCE-UHFFFAOYSA-N 0.000 description 1
- NBEQHBYMYSJVDJ-UHFFFAOYSA-N C(C)(C)C(=O)O.FC(OC1=NC=CC=C1C1=CN=C2N1N=C(C=C2)N2CCNCC2)F Chemical compound C(C)(C)C(=O)O.FC(OC1=NC=CC=C1C1=CN=C2N1N=C(C=C2)N2CCNCC2)F NBEQHBYMYSJVDJ-UHFFFAOYSA-N 0.000 description 1
- FKALYCZQWOTTFE-UHFFFAOYSA-N C(C)(C)C(=O)O.FC1=C(C=CC=C1OC)C1=CN=C2N1N=C(C=C2)N2CCNCC2 Chemical compound C(C)(C)C(=O)O.FC1=C(C=CC=C1OC)C1=CN=C2N1N=C(C=C2)N2CCNCC2 FKALYCZQWOTTFE-UHFFFAOYSA-N 0.000 description 1
- WTPJUUIUHDLZQU-UHFFFAOYSA-N C(C)(C)C(=O)O.FC1=CC=C(C=N1)C=1C=NN2C1N=C(C=C2)N2CCNCC2 Chemical compound C(C)(C)C(=O)O.FC1=CC=C(C=N1)C=1C=NN2C1N=C(C=C2)N2CCNCC2 WTPJUUIUHDLZQU-UHFFFAOYSA-N 0.000 description 1
- MGESICNHPQCIFO-UHFFFAOYSA-N C(C)(C)C(=O)O.FC=1C=C(C=NC1)C=1C=NN2C1N=C(C=C2)N2CCNCC2 Chemical compound C(C)(C)C(=O)O.FC=1C=C(C=NC1)C=1C=NN2C1N=C(C=C2)N2CCNCC2 MGESICNHPQCIFO-UHFFFAOYSA-N 0.000 description 1
- VIRJCIGVBKCTMG-UHFFFAOYSA-N C(C)(C)C(=O)O.N1=C(C=NC=C1)C=1C=NN2C1N=C(C=C2)N2CCNCC2 Chemical compound C(C)(C)C(=O)O.N1=C(C=NC=C1)C=1C=NN2C1N=C(C=C2)N2CCNCC2 VIRJCIGVBKCTMG-UHFFFAOYSA-N 0.000 description 1
- MNOIYSCBGYEFNT-UHFFFAOYSA-N C(C)(C)C(=O)O.N1=CN=CC(=C1)C=1C=NN2C1N=C(C=C2)N2CCNCC2 Chemical compound C(C)(C)C(=O)O.N1=CN=CC(=C1)C=1C=NN2C1N=C(C=C2)N2CCNCC2 MNOIYSCBGYEFNT-UHFFFAOYSA-N 0.000 description 1
- SDPBAAOJAKVKNH-UHFFFAOYSA-N C(C)(C)C(=O)O.O1COC2=C1C=CC=C2C2=CN=C1N2N=C(C=C1)N1CCNCC1 Chemical compound C(C)(C)C(=O)O.O1COC2=C1C=CC=C2C2=CN=C1N2N=C(C=C1)N1CCNCC1 SDPBAAOJAKVKNH-UHFFFAOYSA-N 0.000 description 1
- FFXPDEBVIPUAMF-UHFFFAOYSA-N C(C)(C)C(=O)O.O=C1NC=CC=C1C1=CN=C2N1N=C(C=C2)N2CCNCC2 Chemical compound C(C)(C)C(=O)O.O=C1NC=CC=C1C1=CN=C2N1N=C(C=C2)N2CCNCC2 FFXPDEBVIPUAMF-UHFFFAOYSA-N 0.000 description 1
- DLTGMHKTGGSXTM-UHFFFAOYSA-N CC(C)CCC(=O)c1cccc(c1)-c1ccc2ncc(-c3ccc(CN)cc3)n2n1 Chemical compound CC(C)CCC(=O)c1cccc(c1)-c1ccc2ncc(-c3ccc(CN)cc3)n2n1 DLTGMHKTGGSXTM-UHFFFAOYSA-N 0.000 description 1
- XZUAAMGVSVNFEF-UHFFFAOYSA-N CC(C)CNC(=O)c1cncc(c1)-c1ccc2ncc(-c3ccc(CN)cc3)n2n1 Chemical compound CC(C)CNC(=O)c1cncc(c1)-c1ccc2ncc(-c3ccc(CN)cc3)n2n1 XZUAAMGVSVNFEF-UHFFFAOYSA-N 0.000 description 1
- JFMVBAMEKZJNPM-UHFFFAOYSA-N COc1cnccc1-c1cnc2ccc(nn12)-c1cccc(c1)C(=O)CCC(C)C Chemical compound COc1cnccc1-c1cnc2ccc(nn12)-c1cccc(c1)C(=O)CCC(C)C JFMVBAMEKZJNPM-UHFFFAOYSA-N 0.000 description 1
- 101100000320 Caenorhabditis elegans aak-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000005853 Clathrin Human genes 0.000 description 1
- 108010019874 Clathrin Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- OCDGGHNMAKHEGH-LBPRGKRZSA-N FC(CC(=O)N(C)[C@@H]1CN(CC1)C=1C=CC=2N(N=1)C(=CN=2)C=1C(=NC=CC=1)O)(F)F Chemical compound FC(CC(=O)N(C)[C@@H]1CN(CC1)C=1C=CC=2N(N=1)C(=CN=2)C=1C(=NC=CC=1)O)(F)F OCDGGHNMAKHEGH-LBPRGKRZSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- LFEVDIYPKRIWIG-UHFFFAOYSA-N N'-[[4-[6-(3,3-dimethylbutylamino)imidazo[1,2-b]pyridazin-3-yl]phenyl]methyl]ethane-1,2-diamine Chemical compound CC(CCNC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(CNCCN)C=C1)(C)C LFEVDIYPKRIWIG-UHFFFAOYSA-N 0.000 description 1
- LJQKQWSDCISIRH-UHFFFAOYSA-N N'-[[4-[6-(butylamino)imidazo[1,2-b]pyridazin-3-yl]phenyl]methyl]ethane-1,2-diamine Chemical compound C(CCC)NC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(CNCCN)C=C1 LJQKQWSDCISIRH-UHFFFAOYSA-N 0.000 description 1
- RKJMLTBRHMKBGS-UHFFFAOYSA-N N'-[[4-[6-(butylamino)imidazo[1,2-b]pyridazin-3-yl]phenyl]methyl]propane-1,3-diamine Chemical compound C(CCC)NC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(CNCCCN)C=C1 RKJMLTBRHMKBGS-UHFFFAOYSA-N 0.000 description 1
- NVTPWPJIWHCUCH-UHFFFAOYSA-N N-(2-aminoethyl)-4-[5-(butylamino)pyrazolo[1,5-a]pyrimidin-3-yl]benzamide Chemical compound NCCNC(C1=CC=C(C=C1)C=1C=NN2C=1N=C(C=C2)NCCCC)=O NVTPWPJIWHCUCH-UHFFFAOYSA-N 0.000 description 1
- QGNHGHWBQMIFOE-UHFFFAOYSA-N N-(2-aminoethyl)-4-[6-(butylamino)imidazo[1,2-b]pyridazin-3-yl]-2-fluorobenzamide Chemical compound NCCNC(C1=C(C=C(C=C1)C1=CN=C2N1N=C(C=C2)NCCCC)F)=O QGNHGHWBQMIFOE-UHFFFAOYSA-N 0.000 description 1
- YKYGIPOKDMFZDZ-UHFFFAOYSA-N N-(2-aminoethyl)-4-[6-(butylamino)imidazo[1,2-b]pyridazin-3-yl]-2-methoxybenzamide Chemical compound NCCNC(C1=C(C=C(C=C1)C1=CN=C2N1N=C(C=C2)NCCCC)OC)=O YKYGIPOKDMFZDZ-UHFFFAOYSA-N 0.000 description 1
- GQKXIRZMTQVQKM-UHFFFAOYSA-N N-(2-aminoethyl)-4-[6-(butylamino)imidazo[1,2-b]pyridazin-3-yl]-3-fluorobenzamide Chemical compound NCCNC(C1=CC(=C(C=C1)C1=CN=C2N1N=C(C=C2)NCCCC)F)=O GQKXIRZMTQVQKM-UHFFFAOYSA-N 0.000 description 1
- CJIWQWKYLGHJIK-UHFFFAOYSA-N N-(2-aminopropyl)-4-[6-(butylamino)imidazo[1,2-b]pyridazin-3-yl]benzamide Chemical compound NC(CNC(C1=CC=C(C=C1)C1=CN=C2N1N=C(C=C2)NCCCC)=O)C CJIWQWKYLGHJIK-UHFFFAOYSA-N 0.000 description 1
- QNDSIZPMLUHPSK-UHFFFAOYSA-N N-(2-cyclopentyloxyethyl)-3-(1H-pyrazol-5-yl)imidazo[1,2-b]pyridazin-6-amine Chemical compound C1(CCCC1)OCCNC=1C=CC=2N(N=1)C(=CN=2)C1=NNC=C1 QNDSIZPMLUHPSK-UHFFFAOYSA-N 0.000 description 1
- XUZLMZFHAUKJBM-UHFFFAOYSA-N N-(2-cyclopentyloxyethyl)-3-(2-fluoropyridin-3-yl)imidazo[1,2-b]pyridazin-6-amine Chemical compound C1(CCCC1)OCCNC=1C=CC=2N(N=1)C(=CN=2)C=1C(=NC=CC=1)F XUZLMZFHAUKJBM-UHFFFAOYSA-N 0.000 description 1
- XJCQZHXAJZPPAH-UHFFFAOYSA-N N-(2-cyclopentyloxyethyl)-3-(3-fluoropyridin-4-yl)imidazo[1,2-b]pyridazin-6-amine Chemical compound C1(CCCC1)OCCNC=1C=CC=2N(N=1)C(=CN=2)C1=C(C=NC=C1)F XJCQZHXAJZPPAH-UHFFFAOYSA-N 0.000 description 1
- GZSFFOAETZSCHC-UHFFFAOYSA-N N-(2-cyclopentyloxyethyl)-3-(3-methoxypyridin-4-yl)imidazo[1,2-b]pyridazin-6-amine Chemical compound C1(CCCC1)OCCNC=1C=CC=2N(N=1)C(=CN=2)C1=C(C=NC=C1)OC GZSFFOAETZSCHC-UHFFFAOYSA-N 0.000 description 1
- BRVHUOROTUOMGK-UHFFFAOYSA-N N-(2-cyclopentyloxyethyl)-3-(3-methoxypyridin-4-yl)pyrazolo[1,5-a]pyrimidin-5-amine Chemical compound C1(CCCC1)OCCNC1=NC=2N(C=C1)N=CC=2C1=C(C=NC=C1)OC BRVHUOROTUOMGK-UHFFFAOYSA-N 0.000 description 1
- VIXIHGWKRZRQOX-UHFFFAOYSA-N N-(2-cyclopentyloxyethyl)-3-(4-methylthiophen-2-yl)imidazo[1,2-b]pyridazin-6-amine Chemical compound C1(CCCC1)OCCNC=1C=CC=2N(N=1)C(=CN=2)C=1SC=C(C=1)C VIXIHGWKRZRQOX-UHFFFAOYSA-N 0.000 description 1
- BQNUKZJYIRHMKO-UHFFFAOYSA-N N-(2-cyclopentyloxyethyl)-3-(4-pyrrolidin-2-ylphenyl)imidazo[1,2-b]pyridazin-6-amine Chemical compound C1(CCCC1)OCCNC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(C=C1)C1NCCC1 BQNUKZJYIRHMKO-UHFFFAOYSA-N 0.000 description 1
- VITJZNAIDKGQSI-UHFFFAOYSA-N N-(2-cyclopentyloxyethyl)-3-(5-methoxypyridin-3-yl)imidazo[1,2-b]pyridazin-6-amine Chemical compound C1(CCCC1)OCCNC=1C=CC=2N(N=1)C(=CN=2)C=1C=NC=C(C=1)OC VITJZNAIDKGQSI-UHFFFAOYSA-N 0.000 description 1
- VPZKHUVXXTZBRI-UHFFFAOYSA-N N-(2-cyclopentyloxyethyl)-3-(5-methylthiophen-2-yl)imidazo[1,2-b]pyridazin-6-amine Chemical compound C1(CCCC1)OCCNC=1C=CC=2N(N=1)C(=CN=2)C=1SC(=CC=1)C VPZKHUVXXTZBRI-UHFFFAOYSA-N 0.000 description 1
- WWBMUQRRWMQPKA-UHFFFAOYSA-N N-(2-cyclopentyloxyethyl)-3-pyridin-2-ylimidazo[1,2-b]pyridazin-6-amine Chemical compound C1(CCCC1)OCCNC=1C=CC=2N(N=1)C(=CN=2)C1=NC=CC=C1 WWBMUQRRWMQPKA-UHFFFAOYSA-N 0.000 description 1
- ZJSIVIFFZQJSMP-UHFFFAOYSA-N N-(2-cyclopentyloxyethyl)-3-thiophen-2-ylimidazo[1,2-b]pyridazin-6-amine Chemical compound C1(CCCC1)OCCNC=1C=CC=2N(N=1)C(=CN=2)C=1SC=CC=1 ZJSIVIFFZQJSMP-UHFFFAOYSA-N 0.000 description 1
- GVGWDRGBUZXLGA-UHFFFAOYSA-N N-(2-cyclopentyloxyethyl)-3-thiophen-3-ylimidazo[1,2-b]pyridazin-6-amine Chemical compound C1(CCCC1)OCCNC=1C=CC=2N(N=1)C(=CN=2)C1=CSC=C1 GVGWDRGBUZXLGA-UHFFFAOYSA-N 0.000 description 1
- CZJSLBDCPHNZDG-UHFFFAOYSA-N N-(2-methoxyethyl)-3-phenylpyrazolo[1,5-a]pyrimidin-5-amine Chemical compound COCCNC1=NC=2N(C=C1)N=CC=2C1=CC=CC=C1 CZJSLBDCPHNZDG-UHFFFAOYSA-N 0.000 description 1
- MBGIHQDKLXHUAL-UHFFFAOYSA-N N-(2-propan-2-yloxyethyl)-3-(1,3-thiazol-4-yl)imidazo[1,2-b]pyridazin-6-amine Chemical compound C(C)(C)OCCNC=1C=CC=2N(N=1)C(=CN=2)C=1N=CSC=1 MBGIHQDKLXHUAL-UHFFFAOYSA-N 0.000 description 1
- OSAWHIIAAQFWJG-UHFFFAOYSA-N N-(2-propan-2-yloxyethyl)-3-(1H-pyrazol-5-yl)imidazo[1,2-b]pyridazin-6-amine Chemical compound C(C)(C)OCCNC=1C=CC=2N(N=1)C(=CN=2)C1=NNC=C1 OSAWHIIAAQFWJG-UHFFFAOYSA-N 0.000 description 1
- IWOLSKZGSBHCEH-UHFFFAOYSA-N N-(2-propan-2-yloxyethyl)-3-(4-pyrrolidin-2-ylphenyl)imidazo[1,2-b]pyridazin-6-amine Chemical compound C(C)(C)OCCNC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(C=C1)C1NCCC1 IWOLSKZGSBHCEH-UHFFFAOYSA-N 0.000 description 1
- CXDBCDPUIGKXCG-UHFFFAOYSA-N N-(3,3-dimethylbutyl)-3-(4-pyrrolidin-2-ylphenyl)imidazo[1,2-b]pyridazin-6-amine Chemical compound CC(CCNC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(C=C1)C1NCCC1)(C)C CXDBCDPUIGKXCG-UHFFFAOYSA-N 0.000 description 1
- XQSXFTBESMRBST-UHFFFAOYSA-N N-(3,3-dimethylbutyl)-3-[4-[2-(methylamino)ethoxymethyl]phenyl]imidazo[1,2-b]pyridazin-6-amine Chemical compound CC(CCNC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(C=C1)COCCNC)(C)C XQSXFTBESMRBST-UHFFFAOYSA-N 0.000 description 1
- HLPKFNNEGSUAJN-UHFFFAOYSA-N N-(3-aminopropyl)-4-[6-(butylamino)imidazo[1,2-b]pyridazin-3-yl]benzamide Chemical compound NCCCNC(C1=CC=C(C=C1)C1=CN=C2N1N=C(C=C2)NCCCC)=O HLPKFNNEGSUAJN-UHFFFAOYSA-N 0.000 description 1
- VFLHWHAQLBZJGX-UHFFFAOYSA-N N-(3-cyclopentyloxypropyl)-3-(3-methoxypyridin-4-yl)pyrazolo[1,5-a]pyrimidin-5-amine Chemical compound C1(CCCC1)OCCCNC1=NC=2N(C=C1)N=CC=2C1=C(C=NC=C1)OC VFLHWHAQLBZJGX-UHFFFAOYSA-N 0.000 description 1
- UZSYLLZAICGKFM-UHFFFAOYSA-N N-(3-fluoropropyl)-3-(4-pyrrolidin-2-ylphenyl)imidazo[1,2-b]pyridazin-6-amine Chemical compound FCCCNC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(C=C1)C1NCCC1 UZSYLLZAICGKFM-UHFFFAOYSA-N 0.000 description 1
- VJVZBIVGVDSFMT-UHFFFAOYSA-N N-(3-phenylpropyl)-3-(4-pyrrolidin-2-ylphenyl)imidazo[1,2-b]pyridazin-6-amine Chemical compound C1(=CC=CC=C1)CCCNC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(C=C1)C1NCCC1 VJVZBIVGVDSFMT-UHFFFAOYSA-N 0.000 description 1
- DZWOIWSCZFTAHH-RBUKOAKNSA-N N-[(1R,2S)-2-aminocyclohexyl]-4-[6-(butylamino)imidazo[1,2-b]pyridazin-3-yl]benzamide Chemical compound N[C@@H]1[C@@H](CCCC1)NC(C1=CC=C(C=C1)C1=CN=C2N1N=C(C=C2)NCCCC)=O DZWOIWSCZFTAHH-RBUKOAKNSA-N 0.000 description 1
- OODSFSVAXGVJGG-NSHDSACASA-N N-[(3S)-1-(3-bromoimidazo[1,2-b]pyridazin-6-yl)pyrrolidin-3-yl]-N-methylbutanamide Chemical compound CCCC(=O)N(C)[C@H]1CCN(C1)c1ccc2ncc(Br)n2n1 OODSFSVAXGVJGG-NSHDSACASA-N 0.000 description 1
- POJIUBFJVZVOCE-HNNXBMFYSA-N N-[(3S)-1-[3-(2-methoxypyridin-3-yl)imidazo[1,2-b]pyridazin-6-yl]pyrrolidin-3-yl]-N-methylbutanamide Chemical compound COC1=NC=CC=C1C1=CN=C2N1N=C(C=C2)N1C[C@H](CC1)N(C(CCC)=O)C POJIUBFJVZVOCE-HNNXBMFYSA-N 0.000 description 1
- PUXKZLLAKVPVJC-UHFFFAOYSA-N N-[2-(2-ethoxyphenyl)ethyl]-3-(3-methoxypyridin-4-yl)imidazo[1,2-b]pyridazin-6-amine Chemical compound C(C)OC1=C(C=CC=C1)CCNC=1C=CC=2N(N=1)C(=CN=2)C1=C(C=NC=C1)OC PUXKZLLAKVPVJC-UHFFFAOYSA-N 0.000 description 1
- HRYGMZFGGFGSMK-UHFFFAOYSA-N N-[2-(2-methylpropoxy)ethyl]-3-pyridin-4-ylimidazo[1,2-b]pyridazin-6-amine Chemical compound C(C(C)C)OCCNC=1C=CC=2N(N=1)C(=CN=2)C1=CC=NC=C1 HRYGMZFGGFGSMK-UHFFFAOYSA-N 0.000 description 1
- CQDGNPYDLBZMJM-UHFFFAOYSA-N N-[2-[(2-methylpropan-2-yl)oxy]ethyl]-3-(4-pyrrolidin-2-ylphenyl)imidazo[1,2-b]pyridazin-6-amine Chemical compound C(C)(C)(C)OCCNC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(C=C1)C1NCCC1 CQDGNPYDLBZMJM-UHFFFAOYSA-N 0.000 description 1
- YLYOQCUANHAMBV-UHFFFAOYSA-N N-[2-[[3-(4-cyanophenyl)imidazo[1,2-b]pyridazin-6-yl]amino]ethyl]-N,2,2-trimethylpropanamide Chemical compound C(#N)C1=CC=C(C=C1)C1=CN=C2N1N=C(C=C2)NCCN(C(C(C)(C)C)=O)C YLYOQCUANHAMBV-UHFFFAOYSA-N 0.000 description 1
- MAHIJCHNLGPOBE-UHFFFAOYSA-N N-[2-[[3-(4-cyanophenyl)imidazo[1,2-b]pyridazin-6-yl]amino]ethyl]-N,3,3-trimethylbutanamide Chemical compound C(#N)C1=CC=C(C=C1)C1=CN=C2N1N=C(C=C2)NCCN(C(CC(C)(C)C)=O)C MAHIJCHNLGPOBE-UHFFFAOYSA-N 0.000 description 1
- ITOKSAWCSMZLRG-UHFFFAOYSA-N N-[3-[4-(aminomethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]-N'-methyl-N'-phenylethane-1,2-diamine Chemical compound NCC1=CC=C(C=C1)C1=CN=C2N1N=C(C=C2)NCCN(C1=CC=CC=C1)C ITOKSAWCSMZLRG-UHFFFAOYSA-N 0.000 description 1
- BFMSNDXFSFTTGG-UHFFFAOYSA-N N-[3-[[3-[4-(aminomethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]amino]propyl]-N,2,2-trimethylpropanamide Chemical compound NCC1=CC=C(C=C1)C1=CN=C2N1N=C(C=C2)NCCCN(C(C(C)(C)C)=O)C BFMSNDXFSFTTGG-UHFFFAOYSA-N 0.000 description 1
- GBQWWBJMPAMACV-UHFFFAOYSA-N N-[4-(2-aminoethoxy)phenyl]-6-(butylamino)imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound NCCOC1=CC=C(C=C1)NC(=O)C1=CN=C2N1N=C(C=C2)NCCCC GBQWWBJMPAMACV-UHFFFAOYSA-N 0.000 description 1
- GNMJASBLNAFMPK-UHFFFAOYSA-N N-butyl-3-(3-methoxypyridin-4-yl)imidazo[1,2-b]pyridazin-6-amine Chemical compound C(CCC)NC=1C=CC=2N(N=1)C(=CN=2)C1=C(C=NC=C1)OC GNMJASBLNAFMPK-UHFFFAOYSA-N 0.000 description 1
- CFWOVIFVVJGZBA-UHFFFAOYSA-N N-butyl-3-(4-pyrrolidin-2-ylphenyl)imidazo[1,2-b]pyridazin-6-amine Chemical compound C(CCC)NC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(C=C1)C1NCCC1 CFWOVIFVVJGZBA-UHFFFAOYSA-N 0.000 description 1
- JBSPMYVMMDCTFO-UHFFFAOYSA-N N-butyl-3-[4-(propylaminomethyl)phenyl]imidazo[1,2-b]pyridazin-6-amine Chemical compound C(CCC)NC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(C=C1)CNCCC JBSPMYVMMDCTFO-UHFFFAOYSA-N 0.000 description 1
- CFWOVIFVVJGZBA-QGZVFWFLSA-N N-butyl-3-[4-[(2R)-pyrrolidin-2-yl]phenyl]imidazo[1,2-b]pyridazin-6-amine Chemical compound C(CCC)NC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(C=C1)[C@@H]1NCCC1 CFWOVIFVVJGZBA-QGZVFWFLSA-N 0.000 description 1
- CFWOVIFVVJGZBA-KRWDZBQOSA-N N-butyl-3-[4-[(2S)-pyrrolidin-2-yl]phenyl]imidazo[1,2-b]pyridazin-6-amine Chemical compound C(CCC)NC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(C=C1)[C@H]1NCCC1 CFWOVIFVVJGZBA-KRWDZBQOSA-N 0.000 description 1
- SMFWPAJDZJCMHL-UHFFFAOYSA-N N-butyl-3-[4-[(propan-2-ylamino)methyl]phenyl]imidazo[1,2-b]pyridazin-6-amine Chemical compound C(CCC)NC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(C=C1)CNC(C)C SMFWPAJDZJCMHL-UHFFFAOYSA-N 0.000 description 1
- CDCYYWFTHIIZMO-UHFFFAOYSA-N N-methyl-4-[6-[2-[(2-methylpropan-2-yl)oxy]ethylamino]imidazo[1,2-b]pyridazin-3-yl]benzamide Chemical compound C(C)(C)(C)OCCNC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(C(=O)NC)C=C1 CDCYYWFTHIIZMO-UHFFFAOYSA-N 0.000 description 1
- OZCGCXVWAPMRRG-INIZCTEOSA-N N-methyl-N-[(3S)-1-[3-(2-oxo-1H-pyridin-3-yl)imidazo[1,2-b]pyridazin-6-yl]pyrrolidin-3-yl]cyclopentanecarboxamide Chemical compound C([C@@H](C1)N(C)C(=O)C2CCCC2)CN1C(=NN12)C=CC1=NC=C2C1=CC=CN=C1O OZCGCXVWAPMRRG-INIZCTEOSA-N 0.000 description 1
- GUTKIXYKOANVJW-UHFFFAOYSA-N N-tert-butyl-4-[3-(2-methoxypyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl]-N-methylpiperazine-1-carboxamide Chemical compound C(C)(C)(C)N(C(=O)N1CCN(CC1)C1=NC=2N(C=C1)N=CC=2C=1C(=NC=CC=1)OC)C GUTKIXYKOANVJW-UHFFFAOYSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 102000048238 Neuregulin-1 Human genes 0.000 description 1
- 108090000556 Neuregulin-1 Proteins 0.000 description 1
- KRPWRTLMZACCPW-HNNXBMFYSA-N OC1=NC=CC=C1C1=CN=C2N1N=C(C=C2)N1C[C@H](CC1)N(C(CC(C)(C)C)=O)C Chemical compound OC1=NC=CC=C1C1=CN=C2N1N=C(C=C2)N1C[C@H](CC1)N(C(CC(C)(C)C)=O)C KRPWRTLMZACCPW-HNNXBMFYSA-N 0.000 description 1
- BIMUIMNSTKIUGL-HNNXBMFYSA-N OC1=NC=CC=C1C1=CN=C2N1N=C(C=C2)N1C[C@H](CC1)N(C(CC(C)C)=O)C Chemical compound OC1=NC=CC=C1C1=CN=C2N1N=C(C=C2)N1C[C@H](CC1)N(C(CC(C)C)=O)C BIMUIMNSTKIUGL-HNNXBMFYSA-N 0.000 description 1
- UFNKGYPIYLCLHE-AWEZNQCLSA-N OC1=NC=CC=C1C1=CN=C2N1N=C(C=C2)N1C[C@H](CC1)N(C(CCC)=O)C Chemical compound OC1=NC=CC=C1C1=CN=C2N1N=C(C=C2)N1C[C@H](CC1)N(C(CCC)=O)C UFNKGYPIYLCLHE-AWEZNQCLSA-N 0.000 description 1
- MBVFSVDEVKVGSD-ZDUSSCGKSA-N OC1=NC=CC=C1C1=CN=C2N1N=C(C=C2)N1C[C@H](CC1)N(C(COC)=O)C Chemical compound OC1=NC=CC=C1C1=CN=C2N1N=C(C=C2)N1C[C@H](CC1)N(C(COC)=O)C MBVFSVDEVKVGSD-ZDUSSCGKSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- DDZRCHKYWPEAGY-UHFFFAOYSA-N [4-(3-phenylimidazo[1,2-b]pyridazin-6-yl)piperazin-1-yl]-piperidin-1-ylmethanone Chemical compound C1(=CC=CC=C1)C1=CN=C2N1N=C(C=C2)N1CCN(CC1)C(=O)N1CCCCC1 DDZRCHKYWPEAGY-UHFFFAOYSA-N 0.000 description 1
- PYWMDOIAOLNLTD-UHFFFAOYSA-N [4-(3-phenylimidazo[1,2-b]pyridazin-6-yl)piperazin-1-yl]-pyrrolidin-1-ylmethanone Chemical compound C1CN(C2=NN3C(C=4C=CC=CC=4)=CN=C3C=C2)CCN1C(=O)N1CCCC1 PYWMDOIAOLNLTD-UHFFFAOYSA-N 0.000 description 1
- YRLQBLKDFRPCBZ-UHFFFAOYSA-N [4-(3-pyridin-2-ylimidazo[1,2-b]pyridazin-6-yl)piperazin-1-yl]-pyrrolidin-1-ylmethanone Chemical compound C1CN(C2=NN3C(C=4N=CC=CC=4)=CN=C3C=C2)CCN1C(=O)N1CCCC1 YRLQBLKDFRPCBZ-UHFFFAOYSA-N 0.000 description 1
- ODODEAIDNDYLPR-UHFFFAOYSA-N [4-(6-butylsulfanylimidazo[1,2-b]pyridazin-3-yl)phenyl]methanamine Chemical compound C(CCC)SC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(C=C1)CN ODODEAIDNDYLPR-UHFFFAOYSA-N 0.000 description 1
- LARDYNAJIJPZTF-UHFFFAOYSA-N [4-[3-(2-methoxyphenyl)imidazo[1,2-b]pyridazin-6-yl]piperazin-1-yl]-piperidin-1-ylmethanone Chemical compound COC1=C(C=CC=C1)C1=CN=C2N1N=C(C=C2)N1CCN(CC1)C(=O)N1CCCCC1 LARDYNAJIJPZTF-UHFFFAOYSA-N 0.000 description 1
- GNVZGODDYSQNNT-UHFFFAOYSA-N [4-[3-(2-methoxyphenyl)imidazo[1,2-b]pyridazin-6-yl]piperazin-1-yl]-pyrrolidin-1-ylmethanone Chemical compound COC1=C(C=CC=C1)C1=CN=C2N1N=C(C=C2)N1CCN(CC1)C(=O)N1CCCC1 GNVZGODDYSQNNT-UHFFFAOYSA-N 0.000 description 1
- KVQIPWYZRNMXEY-UHFFFAOYSA-N [4-[3-(2-methoxypyridin-3-yl)imidazo[1,2-b]pyridazin-6-yl]piperazin-1-yl]-piperidin-1-ylmethanone Chemical compound COC1=NC=CC=C1C1=CN=C2N1N=C(C=C2)N1CCN(CC1)C(=O)N1CCCCC1 KVQIPWYZRNMXEY-UHFFFAOYSA-N 0.000 description 1
- DRPUPLZYNVEMNM-UHFFFAOYSA-N [4-[3-(2-methoxypyridin-3-yl)imidazo[1,2-b]pyridazin-6-yl]piperazin-1-yl]-pyrrolidin-1-ylmethanone Chemical compound COC1=NC=CC=C1C1=CN=C2N1N=C(C=C2)N1CCN(CC1)C(=O)N1CCCC1 DRPUPLZYNVEMNM-UHFFFAOYSA-N 0.000 description 1
- HRPCQOYHKHAFMK-UHFFFAOYSA-N [4-[3-(3-methoxypyridin-4-yl)imidazo[1,2-b]pyridazin-6-yl]piperazin-1-yl]-pyrrolidin-1-ylmethanone Chemical compound COC=1C=NC=CC=1C1=CN=C2N1N=C(C=C2)N1CCN(CC1)C(=O)N1CCCC1 HRPCQOYHKHAFMK-UHFFFAOYSA-N 0.000 description 1
- YFTYWHJDXJOMPI-UHFFFAOYSA-N [4-[6-(2-cyclopentyloxyethylamino)imidazo[1,2-b]pyridazin-3-yl]phenyl]methanol Chemical compound C1(CCCC1)OCCNC=1C=CC=2N(N=1)C(=CN=2)C1=CC=C(C=C1)CO YFTYWHJDXJOMPI-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005163 aryl sulfanyl group Chemical group 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- KVVMXWRFYAGASO-UHFFFAOYSA-N azetidine-1-carboxylic acid Chemical compound OC(=O)N1CCC1 KVVMXWRFYAGASO-UHFFFAOYSA-N 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229930193282 clathrin Natural products 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 238000003350 crude synaptosomal preparation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- TWVHNUHPWZPERN-UHFFFAOYSA-N ethyl 4-(3-phenylimidazo[1,2-b]pyridazin-6-yl)piperazine-1-carboxylate Chemical compound C1(=CC=CC=C1)C1=CN=C2N1N=C(C=C2)N1CCN(CC1)C(=O)OCC TWVHNUHPWZPERN-UHFFFAOYSA-N 0.000 description 1
- QABDGZBPLZKWEG-UHFFFAOYSA-N ethyl 4-[3-(methylcarbamoyl)imidazo[1,2-b]pyridazin-6-yl]piperazine-1-carboxylate Chemical compound CNC(=O)C1=CN=C2N1N=C(C=C2)N1CCN(CC1)C(=O)OCC QABDGZBPLZKWEG-UHFFFAOYSA-N 0.000 description 1
- QDTTYLIRCCWXTB-UHFFFAOYSA-N ethyl 4-[[3-[4-(aminomethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]amino]butanoate Chemical compound NCC1=CC=C(C=C1)C1=CN=C2N1N=C(C=C2)NCCCC(=O)OCC QDTTYLIRCCWXTB-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical group O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005468 isobutylenyl group Chemical group 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 101150006217 lex1 gene Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- FMOIMBVOPSNDBN-UHFFFAOYSA-N methyl 4-[3-(2-methoxypyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl]piperazine-1-carboxylate Chemical compound COC1=NC=CC=C1C=1C=NN2C=1N=C(C=C2)N1CCN(CC1)C(=O)OC FMOIMBVOPSNDBN-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- UQEIFYRRSNJVDO-UHFFFAOYSA-N n,n-dibenzyl-2-phenylethanamine Chemical compound C=1C=CC=CC=1CN(CC=1C=CC=CC=1)CCC1=CC=CC=C1 UQEIFYRRSNJVDO-UHFFFAOYSA-N 0.000 description 1
- OUYMRXGSRAEFES-UHFFFAOYSA-N n-(2-cyclopentyloxyethyl)-3-(2-methoxypyridin-3-yl)imidazo[1,2-b]pyridazin-6-amine Chemical compound COC1=NC=CC=C1C1=CN=C2N1N=C(NCCOC1CCCC1)C=C2 OUYMRXGSRAEFES-UHFFFAOYSA-N 0.000 description 1
- ZOLJOCMMTJQHBQ-UHFFFAOYSA-N n-(2-propan-2-yloxyethyl)-3-(1,2-thiazol-5-yl)imidazo[1,2-b]pyridazin-6-amine Chemical compound N12N=C(NCCOC(C)C)C=CC2=NC=C1C1=CC=NS1 ZOLJOCMMTJQHBQ-UHFFFAOYSA-N 0.000 description 1
- FCPBMXBGKAZYEB-INIZCTEOSA-N n-[(3s)-1-[3-(2-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-5-yl]pyrrolidin-3-yl]-n-methylbutanamide Chemical compound C1[C@@H](N(C)C(=O)CCC)CCN1C1=NC2=C(C=3C(=CC=CC=3)OC)C=NN2C=C1 FCPBMXBGKAZYEB-INIZCTEOSA-N 0.000 description 1
- GUSUQWMFQDBYLH-INIZCTEOSA-N n-[(3s)-1-[3-(2-methoxypyridin-3-yl)imidazo[1,2-b]pyridazin-6-yl]pyrrolidin-3-yl]-n-methylpyrrolidine-1-carboxamide Chemical compound COC1=NC=CC=C1C1=CN=C2N1N=C(N1C[C@H](CC1)N(C)C(=O)N1CCCC1)C=C2 GUSUQWMFQDBYLH-INIZCTEOSA-N 0.000 description 1
- SYAZAMQPJJQIPU-UHFFFAOYSA-N n-[3-(2-methoxypyridin-3-yl)pyrazolo[1,5-a]pyrimidin-5-yl]-n-(4,4,4-trifluorobutyl)acetamide Chemical compound COC1=NC=CC=C1C1=C2N=C(N(CCCC(F)(F)F)C(C)=O)C=CN2N=C1 SYAZAMQPJJQIPU-UHFFFAOYSA-N 0.000 description 1
- DLAMXDOZXYNMEL-UHFFFAOYSA-N n-[4-(aminomethyl)phenyl]-6-(butylamino)imidazo[1,2-b]pyridazine-3-carboxamide Chemical compound N12N=C(NCCCC)C=CC2=NC=C1C(=O)NC1=CC=C(CN)C=C1 DLAMXDOZXYNMEL-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- IITLHBBBKISCKO-UHFFFAOYSA-N n-butyl-3-(1h-pyrazol-5-yl)imidazo[1,2-b]pyridazin-6-amine Chemical compound N12N=C(NCCCC)C=CC2=NC=C1C=1C=CNN=1 IITLHBBBKISCKO-UHFFFAOYSA-N 0.000 description 1
- LQGBDSHNDULLDL-UHFFFAOYSA-N n-butyl-3-(2,3-dihydro-1h-isoindol-5-yl)imidazo[1,2-b]pyridazin-6-amine Chemical compound C1=C2CNCC2=CC(C2=CN=C3C=CC(=NN32)NCCCC)=C1 LQGBDSHNDULLDL-UHFFFAOYSA-N 0.000 description 1
- WGEAXXXANGTWRT-UHFFFAOYSA-N n-butyl-3-(2,4-dimethyl-1,3-thiazol-5-yl)imidazo[1,2-b]pyridazin-6-amine Chemical compound N12N=C(NCCCC)C=CC2=NC=C1C=1SC(C)=NC=1C WGEAXXXANGTWRT-UHFFFAOYSA-N 0.000 description 1
- PPWVTHJMJZSFHA-UHFFFAOYSA-N n-butyl-3-[4-(2h-tetrazol-5-yl)phenyl]imidazo[1,2-b]pyridazin-6-amine Chemical compound N12N=C(NCCCC)C=CC2=NC=C1C(C=C1)=CC=C1C=1N=NNN=1 PPWVTHJMJZSFHA-UHFFFAOYSA-N 0.000 description 1
- QTHXINJSXGXSBS-UHFFFAOYSA-N n-butyl-3-[4-[(tert-butylamino)methyl]-2-fluorophenyl]imidazo[1,2-b]pyridazin-6-amine Chemical compound N12N=C(NCCCC)C=CC2=NC=C1C1=CC=C(CNC(C)(C)C)C=C1F QTHXINJSXGXSBS-UHFFFAOYSA-N 0.000 description 1
- DTWIPVJNTADKRU-UHFFFAOYSA-N n-butyl-3-[4-[(tert-butylamino)methyl]-3-fluorophenyl]imidazo[1,2-b]pyridazin-6-amine Chemical compound N12N=C(NCCCC)C=CC2=NC=C1C1=CC=C(CNC(C)(C)C)C(F)=C1 DTWIPVJNTADKRU-UHFFFAOYSA-N 0.000 description 1
- SFZWHQLICDPAHB-UHFFFAOYSA-N n-butyl-3-isoquinolin-6-ylimidazo[1,2-b]pyridazin-6-amine Chemical compound C1=NC=CC2=CC(C3=CN=C4C=CC(=NN43)NCCCC)=CC=C21 SFZWHQLICDPAHB-UHFFFAOYSA-N 0.000 description 1
- TYAFEHIORMEOBP-UHFFFAOYSA-N n-pentyl-3-(4-pyrrolidin-2-ylphenyl)imidazo[1,2-b]pyridazin-6-amine Chemical compound N12N=C(NCCCCC)C=CC2=NC=C1C(C=C1)=CC=C1C1CCCN1 TYAFEHIORMEOBP-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- BCZHSIUGXJABNU-UHFFFAOYSA-N piperidin-1-yl-[4-(3-pyridin-2-ylimidazo[1,2-b]pyridazin-6-yl)piperazin-1-yl]methanone Chemical compound N1(CCCCC1)C(=O)N1CCN(CC1)C=1C=CC=2N(N=1)C(=CN=2)C1=NC=CC=C1 BCZHSIUGXJABNU-UHFFFAOYSA-N 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 101150062613 pkn1 gene Proteins 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- DUJFVJKUCHXGJB-NSHDSACASA-N propan-2-yl (2s)-2-[[(3-bromoimidazo[1,2-b]pyridazin-6-yl)amino]methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)OC(=O)N1CCC[C@H]1CNC1=NN2C(Br)=CN=C2C=C1 DUJFVJKUCHXGJB-NSHDSACASA-N 0.000 description 1
- LIWHKLDQEIIMNN-LBPRGKRZSA-N propan-2-yl (2s)-2-[[(3-cyanoimidazo[1,2-b]pyridazin-6-yl)amino]methyl]pyrrolidine-1-carboxylate Chemical compound CC(C)OC(=O)N1CCC[C@H]1CNC1=NN2C(C#N)=CN=C2C=C1 LIWHKLDQEIIMNN-LBPRGKRZSA-N 0.000 description 1
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RYYHBZWQKGJAQV-UHFFFAOYSA-N tert-butyl 2-[2-[[3-(4-carbamoylphenyl)imidazo[1,2-b]pyridazin-6-yl]amino]ethyl]pyrrolidine-1-carboxylate Chemical compound C(N)(=O)C1=CC=C(C=C1)C1=CN=C2N1N=C(C=C2)NCCC1N(CCC1)C(=O)OC(C)(C)C RYYHBZWQKGJAQV-UHFFFAOYSA-N 0.000 description 1
- YEMOUVLLKKCBLG-UHFFFAOYSA-N tert-butyl 2-[2-[[3-[4-(aminomethyl)phenyl]imidazo[1,2-b]pyridazin-6-yl]amino]ethyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1CCNC1=NN2C(C=3C=CC(CN)=CC=3)=CN=C2C=C1 YEMOUVLLKKCBLG-UHFFFAOYSA-N 0.000 description 1
- QQKYPJQBKHFTIB-UHFFFAOYSA-N tert-butyl 4-(3-chloroimidazo[1,2-b]pyridazin-6-yl)piperazine-1-carboxylate Chemical compound ClC1=CN=C2N1N=C(C=C2)N1CCN(CC1)C(=O)OC(C)(C)C QQKYPJQBKHFTIB-UHFFFAOYSA-N 0.000 description 1
- FKTLVHKODHZFPZ-UHFFFAOYSA-N tert-butyl 4-(3-iodoimidazo[1,2-b]pyridazin-6-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=NN2C(I)=CN=C2C=C1 FKTLVHKODHZFPZ-UHFFFAOYSA-N 0.000 description 1
- JLXJPFBEOCWCNX-UHFFFAOYSA-N tert-butyl 4-(3-phenylimidazo[1,2-b]pyridazin-6-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=NN2C(C=3C=CC=CC=3)=CN=C2C=C1 JLXJPFBEOCWCNX-UHFFFAOYSA-N 0.000 description 1
- RHPVDOKCGXUSSG-UHFFFAOYSA-N tert-butyl 4-[3-(3-methoxypyridin-4-yl)imidazo[1,2-b]pyridazin-6-yl]piperazine-1-carboxylate Chemical compound COC1=CN=CC=C1C1=CN=C2N1N=C(N1CCN(CC1)C(=O)OC(C)(C)C)C=C2 RHPVDOKCGXUSSG-UHFFFAOYSA-N 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- CUPOOAWTRIURFT-UHFFFAOYSA-N thiophene-2-carbonitrile Chemical compound N#CC1=CC=CS1 CUPOOAWTRIURFT-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- 229940066528 trichloroacetate Drugs 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261608849P | 2012-03-09 | 2012-03-09 | |
| US201261608849P | 2012-03-09 | ||
| PCT/US2013/029258 WO2013134336A2 (en) | 2012-03-09 | 2013-03-06 | Inhibition of adaptor associated kinase 1 for the treatment of pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2657061T3 true ES2657061T3 (es) | 2018-03-01 |
Family
ID=47884616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13709722.6T Active ES2657061T3 (es) | 2012-03-09 | 2013-03-06 | Inhibición de la cinasa 1 asociada a adaptador para el tratamiento del dolor |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US20140080834A1 (enExample) |
| EP (2) | EP2822555B1 (enExample) |
| JP (1) | JP2015513557A (enExample) |
| CN (1) | CN104220071A (enExample) |
| AU (1) | AU2013230066A1 (enExample) |
| CA (1) | CA2866145A1 (enExample) |
| DK (1) | DK2822555T3 (enExample) |
| ES (1) | ES2657061T3 (enExample) |
| HK (1) | HK1199814A1 (enExample) |
| HU (1) | HUE036040T2 (enExample) |
| NO (1) | NO2935475T3 (enExample) |
| PL (1) | PL2822555T3 (enExample) |
| PT (1) | PT2822555T (enExample) |
| WO (1) | WO2013134336A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2834243T3 (en) | 2012-03-09 | 2018-07-23 | Lexicon Pharmaceuticals Inc | Pyrazole [1,5-a] pyrimidine-based compounds, compositions comprising them and methods for their use |
| RU2014140739A (ru) * | 2012-03-09 | 2016-04-27 | Лексикон Фармасьютикалз, Инк. | Соединения на основе имидазо[1, 2-b]пиридазина, композиции таких соединений и способы их применения |
| US8901305B2 (en) | 2012-07-31 | 2014-12-02 | Bristol-Myers Squibb Company | Aryl lactam kinase inhibitors |
| EP2958924B1 (en) | 2013-02-22 | 2016-12-28 | Bristol-Myers Squibb Company | 5h-chromeno[3,4-c]pyridines as inhibitors of adaptor associated kinase 1 (aak1) |
| WO2014175370A1 (ja) * | 2013-04-25 | 2014-10-30 | 塩野義製薬株式会社 | ピロリジン誘導体およびそれらを含有する医薬組成物 |
| JP6434968B2 (ja) * | 2013-07-02 | 2018-12-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体 |
| WO2015006100A1 (en) | 2013-07-08 | 2015-01-15 | Bristol-Myers Squibb Company | Aryl amide kinase inhibitors |
| AR097543A1 (es) * | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
| TW201542550A (zh) | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
| MX2016002924A (es) * | 2013-09-11 | 2016-06-06 | Squibb Bristol Myers Co | Inhibidores de cinasa a base de eter arilico. |
| CN105979950A (zh) * | 2013-10-11 | 2016-09-28 | 百时美施贵宝公司 | 吡咯并三嗪激酶抑制剂 |
| ES2701903T3 (es) * | 2014-01-31 | 2019-02-26 | Bristol Myers Squibb Co | Inhibidores de cinasa a base de quinolina |
| TW201620911A (zh) * | 2014-03-17 | 2016-06-16 | 雷西肯製藥股份有限公司 | 銜接子關聯激酶１之抑制劑、包含其之組成物、及其使用方法 |
| CA2944466C (en) * | 2014-04-02 | 2020-06-09 | Bristol-Myers Squibb Company | Biaryl kinase inhibitors |
| US10035777B2 (en) | 2014-08-05 | 2018-07-31 | Bristol-Myers Squibb Company | Heterocyclic kinase inhibitors |
| EP3215511B1 (en) | 2014-11-06 | 2024-04-17 | Bial-R&D Investments, S.A. | Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders |
| EP3292124B1 (en) | 2015-04-10 | 2019-05-22 | Bristol-Myers Squibb Company | 6h-isochromeno[3,4-c]pyridines and benzo[c][1,7]naphthyridin-6-(5h)-ones as adaptor associated kinase 1 (aak1) inhibitors |
| ES2767776T3 (es) | 2015-10-01 | 2020-06-18 | Bristol Myers Squibb Co | Inhibidores de biaril cinasa |
| CN112142655A (zh) | 2015-10-01 | 2020-12-29 | 百时美施贵宝公司 | 联芳基激酶抑制剂 |
| WO2017176961A1 (en) | 2016-04-06 | 2017-10-12 | Lysosomal Therapeutics Inc. | Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| KR20180133461A (ko) | 2016-04-06 | 2018-12-14 | 리소소말 테라퓨틱스 인크. | 피라졸로[1,5-a]피리미디닐 카르복스아미드 화합물 및 의학적 장애의 치료에서의 그의 용도 |
| WO2017192930A1 (en) * | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
| US11352328B2 (en) | 2016-07-12 | 2022-06-07 | Arisan Therapeutics Inc. | Heterocyclic compounds for the treatment of arenavirus |
| US12419865B2 (en) | 2018-12-06 | 2025-09-23 | Arisan Therapeutics Inc. | Compounds for the treatment of arenavirus infection |
| KR102590438B1 (ko) * | 2020-10-16 | 2023-10-18 | 김홍렬 | Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 예방 또는 소독용 조성물 |
| KR102590444B1 (ko) * | 2020-10-16 | 2023-10-18 | 김홍렬 | Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 치료용 조성물 |
| WO2023196584A2 (en) * | 2022-04-08 | 2023-10-12 | New York University | Endocytosis inhibitors and their use for pain treatment |
| WO2025225608A1 (en) * | 2024-04-23 | 2025-10-30 | Otsuka Pharmaceutical Co., Ltd. | Tetrahydropyrazolopyridine derivative |
| WO2025230262A1 (ko) * | 2024-04-29 | 2025-11-06 | 심플렉스 주식회사 | 신규한 헤테로아릴 유도체 및 이의 aak1 억제 용도 |
| WO2026011102A2 (en) * | 2024-07-03 | 2026-01-08 | Board Of Regents, The University Of Texas System | Compositions and methods for treating cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| US20070049591A1 (en) * | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
| BRPI0718266A2 (pt) * | 2006-10-30 | 2014-01-07 | Novartis Ag | Compostos heterocíclicos como agentes anti-inflamatórios. |
| CA2722418C (en) * | 2008-05-13 | 2013-09-17 | Irm Llc | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors |
| US8461336B2 (en) * | 2008-09-04 | 2013-06-11 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
-
2013
- 2013-03-06 HK HK15100206.3A patent/HK1199814A1/xx unknown
- 2013-03-06 PL PL13709722T patent/PL2822555T3/pl unknown
- 2013-03-06 CA CA2866145A patent/CA2866145A1/en not_active Abandoned
- 2013-03-06 EP EP13709722.6A patent/EP2822555B1/en active Active
- 2013-03-06 EP EP17175353.6A patent/EP3235499A3/en not_active Withdrawn
- 2013-03-06 WO PCT/US2013/029258 patent/WO2013134336A2/en not_active Ceased
- 2013-03-06 CN CN201380012478.XA patent/CN104220071A/zh active Pending
- 2013-03-06 PT PT137097226T patent/PT2822555T/pt unknown
- 2013-03-06 US US13/786,575 patent/US20140080834A1/en not_active Abandoned
- 2013-03-06 HU HUE13709722A patent/HUE036040T2/hu unknown
- 2013-03-06 AU AU2013230066A patent/AU2013230066A1/en not_active Abandoned
- 2013-03-06 ES ES13709722.6T patent/ES2657061T3/es active Active
- 2013-03-06 JP JP2014561064A patent/JP2015513557A/ja active Pending
- 2013-03-06 DK DK13709722.6T patent/DK2822555T3/en active
- 2013-12-11 NO NO13811839A patent/NO2935475T3/no unknown
-
2014
- 2014-08-07 US US14/453,666 patent/US20150164899A1/en not_active Abandoned
-
2016
- 2016-02-26 US US15/054,741 patent/US20160206619A1/en not_active Abandoned
-
2018
- 2018-04-30 US US15/966,274 patent/US20190134037A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3235499A3 (en) | 2018-01-17 |
| HK1199814A1 (en) | 2015-07-24 |
| US20140080834A1 (en) | 2014-03-20 |
| JP2015513557A (ja) | 2015-05-14 |
| US20190134037A1 (en) | 2019-05-09 |
| HUE036040T2 (hu) | 2018-06-28 |
| EP2822555B1 (en) | 2017-11-08 |
| CN104220071A (zh) | 2014-12-17 |
| PL2822555T3 (pl) | 2018-04-30 |
| WO2013134336A3 (en) | 2014-03-06 |
| AU2013230066A1 (en) | 2014-09-25 |
| EP2822555A2 (en) | 2015-01-14 |
| CA2866145A1 (en) | 2013-09-12 |
| NO2935475T3 (enExample) | 2017-12-16 |
| WO2013134336A2 (en) | 2013-09-12 |
| EP3235499A2 (en) | 2017-10-25 |
| US20160206619A1 (en) | 2016-07-21 |
| US20150164899A1 (en) | 2015-06-18 |
| DK2822555T3 (en) | 2018-02-05 |
| PT2822555T (pt) | 2018-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2822555B1 (en) | Inhibition of adaptor associated kinase 1 for the treatment of pain | |
| ES2676224T3 (es) | Compuestos a base de pirazolo[1,5-a]pirimidina, composiciones que los comprenden y métodos para usarlos | |
| ES2898771T3 (es) | Indazoles sustituidos útiles para el tratamiento y la prevención de enfermedades alérgicas y/o inflamatorias en animales | |
| ES3009382T3 (en) | Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them and methods of their use | |
| CA2923420A1 (en) | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use | |
| US20250235426A1 (en) | Pharmaceutical Combination and Use Thereof | |
| JP2017507980A (ja) | アダプター関連キナーゼ１の阻害剤、それを含む組成物、及びその使用方法 |